Dianthus Therapeutics Stock Number Of Shares Shorted
| DNTH Stock | 27.38 0.14 0.51% |
Dianthus Therapeutics fundamentals help investors to digest information that contributes to Dianthus Therapeutics' financial success or failures. It also enables traders to predict the movement of Dianthus Stock. The fundamental analysis module provides a way to measure Dianthus Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Dianthus Therapeutics stock.
Dianthus | Number Of Shares Shorted |
Dianthus Therapeutics Company Number Of Shares Shorted Analysis
Dianthus Therapeutics' Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
More About Number Of Shares Shorted | All Equity Analysis
Shares Shorted | = | Shorted by Public | + | by Institutions |
Current Dianthus Therapeutics Number Of Shares Shorted | 4.33 M |
Most of Dianthus Therapeutics' fundamental indicators, such as Number Of Shares Shorted, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Dianthus Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Dianthus Number Of Shares Shorted Driver Correlations
Understanding the fundamental principles of building solid financial models for Dianthus Therapeutics is extremely important. It helps to project a fair market value of Dianthus Stock properly, considering its historical fundamentals such as Number Of Shares Shorted. Since Dianthus Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Dianthus Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Dianthus Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
| Competition |
Based on the recorded statements, Dianthus Therapeutics has 4.33 M of outstending shares currently sold short by investors. This is 35.34% higher than that of the Biotechnology sector and 15.06% lower than that of the Health Care industry. The number of shares shorted for all United States stocks is 7.98% higher than that of the company.
Dianthus Number Of Shares Shorted Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Dianthus Therapeutics' direct or indirect competition against its Number Of Shares Shorted to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Dianthus Therapeutics could also be used in its relative valuation, which is a method of valuing Dianthus Therapeutics by comparing valuation metrics of similar companies.Dianthus Therapeutics is currently under evaluation in number of shares shorted category among its peers.
Dianthus Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Dianthus Therapeutics from analyzing Dianthus Therapeutics' financial statements. These drivers represent accounts that assess Dianthus Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Dianthus Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 561.1M | 344.3M | 243.4M | 5.5M | 53.6M | 50.9M | |
| Enterprise Value | 496.1M | 286.2M | 235.8M | (9.1M) | (78.1M) | (74.2M) |
Dianthus Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Dianthus Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Dianthus Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Dianthus Fundamentals
| Return On Equity | -0.27 | ||||
| Return On Asset | -0.2 | ||||
| Operating Margin | (11.92) % | ||||
| Current Valuation | 439.31 M | ||||
| Shares Outstanding | 29.35 M | ||||
| Shares Owned By Insiders | 8.83 % | ||||
| Shares Owned By Institutions | 91.17 % | ||||
| Number Of Shares Shorted | 4.33 M | ||||
| Price To Book | 2.23 X | ||||
| Price To Sales | 194.17 X | ||||
| Revenue | 2.83 M | ||||
| Gross Profit | 6.42 M | ||||
| EBITDA | (47.82 M) | ||||
| Net Income | (43.55 M) | ||||
| Total Debt | 585 K | ||||
| Book Value Per Share | 12.20 X | ||||
| Cash Flow From Operations | (36.86 M) | ||||
| Short Ratio | 31.65 X | ||||
| Earnings Per Share | (1.93) X | ||||
| Target Price | 50.33 | ||||
| Number Of Employees | 53 | ||||
| Market Capitalization | 799.61 M | ||||
| Total Asset | 179.41 M | ||||
| Retained Earnings | (89.42 M) | ||||
| Working Capital | 167.82 M | ||||
| Net Asset | 179.41 M |
About Dianthus Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Dianthus Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Dianthus Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Dianthus Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Dianthus Stock
When determining whether Dianthus Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Dianthus Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Dianthus Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Dianthus Therapeutics Stock:Check out Dianthus Therapeutics Piotroski F Score and Dianthus Therapeutics Altman Z Score analysis. For more detail on how to invest in Dianthus Stock please use our How to Invest in Dianthus Therapeutics guide.You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dianthus Therapeutics. If investors know Dianthus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dianthus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.93) | Revenue Per Share 0.2 | Quarterly Revenue Growth 0.923 | Return On Assets (0.20) | Return On Equity (0.27) |
The market value of Dianthus Therapeutics is measured differently than its book value, which is the value of Dianthus that is recorded on the company's balance sheet. Investors also form their own opinion of Dianthus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Dianthus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dianthus Therapeutics' market value can be influenced by many factors that don't directly affect Dianthus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dianthus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dianthus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dianthus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.